92 related articles for article (PubMed ID: 30478893)
21. Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data.
Mazurowski MA; Clark K; Czarnek NM; Shamsesfandabadi P; Peters KB; Saha A
J Neurooncol; 2017 May; 133(1):27-35. PubMed ID: 28470431
[TBL] [Abstract][Full Text] [Related]
22. Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy for Differentiating Between Enhanced Gliomas and Malignant Lymphomas.
Ohba S; Murayama K; Abe M; Hasegawa M; Hirose Y
World Neurosurg; 2019 Jul; 127():e779-e787. PubMed ID: 30951915
[TBL] [Abstract][Full Text] [Related]
23. The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family.
van Puijenbroek M; Nielsen M; Reinards TH; Weiss MM; Wagner A; Hendriks YM; Vasen HF; Tops CM; Wijnen J; van Wezel T; Hes FJ; Morreau H
Fam Cancer; 2007; 6(1):43-51. PubMed ID: 17039270
[TBL] [Abstract][Full Text] [Related]
24. Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1.
Krüger S; Kinzel M; Walldorf C; Gottschling S; Bier A; Tinschert S; von Stackelberg A; Henn W; Görgens H; Boue S; Kölble K; Büttner R; Schackert HK
Eur J Hum Genet; 2008 Jan; 16(1):62-72. PubMed ID: 17851451
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K
Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET.
Vettermann FJ; Felsberg J; Reifenberger G; Hasselblatt M; Forbrig R; Berding G; la Fougère C; Galldiks N; Schittenhelm J; Weis J; Albert NL; Schüller U
Clin Nucl Med; 2018 Dec; 43(12):895-898. PubMed ID: 30358620
[TBL] [Abstract][Full Text] [Related]
27. Genetic epidemiology and risk factors for brain tumors.
Li X; Cao H; Liu Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):345-353. PubMed ID: 29774869
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Sun Q; Pei C; Li Q; Dong T; Dong Y; Xing W; Zhou P; Gong Y; Zhen Z; Gao Y; Xiao Y; Su J; Ren H
Biochem Biophys Res Commun; 2018 Feb; 496(4):1040-1046. PubMed ID: 29366782
[TBL] [Abstract][Full Text] [Related]
30. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
31. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
32. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
33. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
[TBL] [Abstract][Full Text] [Related]
34. MSH6 germline mutations are rare in colorectal cancer families.
Peterlongo P; Nafa K; Lerman GS; Glogowski E; Shia J; Ye TZ; Markowitz AJ; Guillem JG; Kolachana P; Boyd JA; Offit K; Ellis NA
Int J Cancer; 2003 Nov; 107(4):571-9. PubMed ID: 14520694
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
36. Frequency of constitutional MSH6 mutations in a consecutive series of families with clinical suspicion of HNPCC.
Roncari B; Pedroni M; Maffei S; Di Gregorio C; Ponti G; Scarselli A; Losi L; Benatti P; Roncucci L; De Gaetani C; Camellini L; Lucci-Cordisco E; Tricarico R; Genuardi M; Ponz de Leon M
Clin Genet; 2007 Sep; 72(3):230-7. PubMed ID: 17718861
[TBL] [Abstract][Full Text] [Related]
37. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.
Hatae R; Hata N; Suzuki SO; Yoshimoto K; Kuga D; Murata H; Akagi Y; Sangatsuda Y; Iwaki T; Mizoguchi M; Iihara K
Neuropathology; 2017 Jun; 37(3):191-199. PubMed ID: 27792249
[TBL] [Abstract][Full Text] [Related]
39. Mapping genetic factors in high-grade glioma patients.
Yuan Y; Yunhe M; Xiang W; Yanhui L; Ruofei L; Jiewen L; Qing M
Clin Neurol Neurosurg; 2016 Nov; 150():159-163. PubMed ID: 27668860
[TBL] [Abstract][Full Text] [Related]
40. Incomplete Segregation of MSH6 Frameshift Variants with Phenotype of Lynch Syndrome.
Liccardo R; De Rosa M; Rossi GB; Carlomagno N; Izzo P; Duraturo F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481244
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
